Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
B RosónF Gudiol

Abstract

Empirical antibiotic therapy of community-acquired pneumonia (CAP) has been complicated by the worldwide emergence of penicillin resistance among Streptococcus pneumoniae. The impact of this resistance on the outcome of patients hospitalized for CAP, empirically treated with betalactams, has not been evaluated in a randomized study. We conducted a prospective, randomized trial to assess the efficacy of amoxicillin-clavulanate (2 g/200 mg/8 hr) and ceftriaxone (1 g/24 hr) in a cohort of patients hospitalized for moderate-to-severe CAP. Three-hundred seventy-eight patients were randomized to receive amoxicillin-clavulanate (184 patients) or ceftriaxone (194 patients). Efficacy was assessed on Day 2, after completion of therapy and at long term follow-up. There were no significant differences in outcomes between treatment groups, both in intention-to-treat and per-protocol analysis. Overall mortality was 10.3% for amoxicillin-clavulanate and 8.8% for ceftriaxone (NS). There were 116 evaluable patients with proven pneumococcal pneumonia. Rates of high-level penicillin resistance (MIC of penicillin > or = 2 microg/mL) were similar in the two groups (8.2 and 10.2%). Clinical efficacy at the end of therapy was 90.6% for amoxicillin-cl...Continue Reading

References

Sep 1, 1992·The Journal of Antimicrobial Chemotherapy·J LiñaresR Martín
Jul 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J LiñaresR Martin
Jul 1, 1989·Reviews of Infectious Diseases·T J MarrieL Yates
Nov 1, 1984·Critical Care Medicine·J R Le GallD Villers
Dec 14, 1995·The New England Journal of Medicine·J G Bartlett, L M Mundy
Jul 1, 1995·Antimicrobial Agents and Chemotherapy·G A PankuchP C Appelbaum
Jan 10, 1996·JAMA : the Journal of the American Medical Association·M J FineW N Kapoor
Nov 1, 1995·Antimicrobial Agents and Chemotherapy·S RadulovicA F Azad
Jan 23, 1997·The New England Journal of Medicine·M J FineW N Kapoor
Jun 13, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G BartlettT M File
Oct 10, 1998·Clinical Microbiology Reviews·S L Kaplan, E O Mason
Oct 27, 1998·Lancet·P D Brown, S A Lerner
Nov 3, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G V DoernR N Jones
Dec 29, 1998·Annals of Internal Medicine·D C Hooper
Feb 13, 1999·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·R PallaresF Gudiol
Nov 30, 1999·The New England Journal of Medicine·G P Oakley
Nov 30, 1999·The New England Journal of Medicine·J LiñaresR Pallares
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W P HausdorffG R Siber

❮ Previous
Next ❯

Citations

Feb 8, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J Garau
Sep 27, 2003·International Journal of Antimicrobial Agents·Roman PallaresUNKNOWN Spanish Pneumococcal Infection Study Network
Feb 1, 2002·Diagnostic Microbiology and Infectious Disease·James A KarlowskyDaniel F Sahm
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN Infectious Diseases Society of America
May 6, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Constance D Rothermel
Dec 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lance R Peterson
Dec 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christine C Chiou
Nov 16, 2004·Critical Care Medicine·Pierre-Yves BochudThierry Calandra
Sep 2, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John S BradleyUNKNOWN Pediatric Infectious Diseases Society and the Infectious Diseases Society of America
Jan 21, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N GoffinetE Montassier
May 12, 2009·Medicina clínica·Jerónimo PachónUNKNOWN Sociedad Andaluza de Medicina Familiar y Comunitaria (SAMFYC)
Nov 19, 2003·Scandinavian Journal of Infectious Diseases·John Turnidge
Sep 1, 2006·Current Opinion in Critical Care·Christine C C Chiou, Victor L Yu
Sep 10, 2005·The Journal of Antimicrobial Chemotherapy·Cristina PichardoJerónimo Pachón
Aug 2, 2017·Expert Opinion on Pharmacotherapy·Bela Kocsis, Dora Szabo
Mar 22, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N Fernández-SabéF Gudiol
Oct 3, 2002·Current Opinion in Critical Care·Santiago Ewig, Antoni Torres
Apr 20, 2002·Current Opinion in Infectious Diseases·Joshua P Metlay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.